DOP2023000251A - Compuestos oligoméricos que inhiben la expresión de hsd17b13 - Google Patents
Compuestos oligoméricos que inhiben la expresión de hsd17b13Info
- Publication number
- DOP2023000251A DOP2023000251A DO2023000251A DO2023000251A DOP2023000251A DO P2023000251 A DOP2023000251 A DO P2023000251A DO 2023000251 A DO2023000251 A DO 2023000251A DO 2023000251 A DO2023000251 A DO 2023000251A DO P2023000251 A DOP2023000251 A DO P2023000251A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- hsd17b13
- expression
- inhibit
- oligomeric compounds
- useful
- Prior art date
Links
- 102100037429 17-beta-hydroxysteroid dehydrogenase 13 Human genes 0.000 title abstract 3
- 101000806241 Homo sapiens 17-beta-hydroxysteroid dehydrogenase 13 Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
Abstract
Se proporciona un compuestos oligomérico o una sal farmacéuticamente aceptable del mismo, con la estructura: y composiciones farmacéuticas que lo comprenden, útiles para inhibir la expresión de HSD17B13 . Tales compuestos y composiciones son útiles para preparar un medicamento para tratar, prevenir o mejorar una enfermedad asociada con HSD17B13.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862783680P | 2018-12-21 | 2018-12-21 | |
US201962825581P | 2019-03-28 | 2019-03-28 | |
US201962827524P | 2019-04-01 | 2019-04-01 | |
PCT/US2019/068051 WO2020132564A1 (en) | 2018-12-21 | 2019-12-20 | Modulators of hsd17b13 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2023000251A true DOP2023000251A (es) | 2023-12-29 |
Family
ID=71102009
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2021000130A DOP2021000130A (es) | 2018-12-21 | 2021-06-21 | Moduladores de la expresion de hsd17b13 |
DO2023000251A DOP2023000251A (es) | 2018-12-21 | 2023-11-14 | Compuestos oligoméricos que inhiben la expresión de hsd17b13 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2021000130A DOP2021000130A (es) | 2018-12-21 | 2021-06-21 | Moduladores de la expresion de hsd17b13 |
Country Status (21)
Country | Link |
---|---|
US (2) | US20220273691A1 (es) |
EP (1) | EP3899024A4 (es) |
JP (2) | JP7394137B2 (es) |
KR (1) | KR20210107027A (es) |
CN (1) | CN113544272A (es) |
AU (2) | AU2019403447B2 (es) |
BR (1) | BR112021011899A2 (es) |
CA (1) | CA3122432A1 (es) |
CL (1) | CL2021001643A1 (es) |
CO (1) | CO2021009009A2 (es) |
CR (1) | CR20210395A (es) |
DO (2) | DOP2021000130A (es) |
EC (1) | ECSP21053104A (es) |
IL (1) | IL283967A (es) |
JO (1) | JOP20210158A1 (es) |
MX (1) | MX2021007503A (es) |
NI (1) | NI202100056A (es) |
PE (1) | PE20211755A1 (es) |
SG (1) | SG11202106378VA (es) |
TW (1) | TW202039846A (es) |
WO (1) | WO2020132564A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3093547A1 (en) * | 2018-03-21 | 2019-09-26 | Ionis Pharmaceuticals, Inc. | Modulation of hsd17b13 expression |
WO2022098748A1 (en) * | 2020-11-06 | 2022-05-12 | Inipharm, Inc. | Uses for hsd17b13 inhibitors |
CN112635049A (zh) * | 2020-12-23 | 2021-04-09 | 无锡市第二人民医院 | 一种研究HSD17B13 rs72613567基因变异和肾功能损伤之间关系的方法 |
WO2023091644A2 (en) * | 2021-11-19 | 2023-05-25 | Wave Life Sciences Ltd. | Hsd17b13-related double stranded oligonucleotide compositions and methods relating thereto |
TW202340470A (zh) * | 2022-01-20 | 2023-10-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一種dsrna、其應用及製備方法 |
TW202400791A (zh) * | 2022-05-06 | 2024-01-01 | 大陸商蘇州瑞博生物技術股份有限公司 | 一種核酸、含有該核酸的組合物與綴合物及製備方法和用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011003071A1 (en) | 2009-07-02 | 2011-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods of modulating hepatitis c virus infection |
DK2855500T3 (da) | 2012-05-24 | 2020-09-14 | Ionis Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression |
CN103520724B (zh) * | 2013-10-23 | 2016-05-25 | 江苏美迪森生物医药有限公司 | Hsd17b13蛋白或其编码基因的抑制剂的新用途 |
RU2019126483A (ru) | 2017-01-23 | 2021-02-24 | Ридженерон Фармасьютикалз, Инк. | Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение |
CN111183234A (zh) | 2017-10-11 | 2020-05-19 | 雷杰纳荣制药公司 | 在表达pnpla3 i148m变异的患者的肝病治疗中对hsd17b13的抑制 |
US20210380985A1 (en) | 2018-03-21 | 2021-12-09 | Regeneron Pharmaceuticals, Inc. | 17ß-Hydroxysteroid Dehydrogenase Type 13 (HSD17B13) iRNA Compositions And Methods Of Use Thereof |
JP7488254B2 (ja) | 2018-09-19 | 2024-05-21 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 17β-HSD13型(HSD17B13)の発現を阻害するためのRNAi剤、その組成物、および使用方法 |
-
2019
- 2019-12-20 EP EP19900290.8A patent/EP3899024A4/en active Pending
- 2019-12-20 PE PE2021000932A patent/PE20211755A1/es unknown
- 2019-12-20 JP JP2021535890A patent/JP7394137B2/ja active Active
- 2019-12-20 MX MX2021007503A patent/MX2021007503A/es unknown
- 2019-12-20 SG SG11202106378VA patent/SG11202106378VA/en unknown
- 2019-12-20 AU AU2019403447A patent/AU2019403447B2/en active Active
- 2019-12-20 CA CA3122432A patent/CA3122432A1/en active Pending
- 2019-12-20 BR BR112021011899-3A patent/BR112021011899A2/pt unknown
- 2019-12-20 WO PCT/US2019/068051 patent/WO2020132564A1/en unknown
- 2019-12-20 CR CR20210395A patent/CR20210395A/es unknown
- 2019-12-20 US US17/416,108 patent/US20220273691A1/en active Pending
- 2019-12-20 JO JOP/2021/0158A patent/JOP20210158A1/ar unknown
- 2019-12-20 CN CN201980083374.5A patent/CN113544272A/zh active Pending
- 2019-12-20 KR KR1020217020646A patent/KR20210107027A/ko unknown
- 2019-12-23 TW TW108147266A patent/TW202039846A/zh unknown
-
2021
- 2021-06-14 IL IL283967A patent/IL283967A/en unknown
- 2021-06-18 CL CL2021001643A patent/CL2021001643A1/es unknown
- 2021-06-21 NI NI202100056A patent/NI202100056A/es unknown
- 2021-06-21 DO DO2021000130A patent/DOP2021000130A/es unknown
- 2021-07-08 CO CONC2021/0009009A patent/CO2021009009A2/es unknown
- 2021-07-19 EC ECSENADI202153104A patent/ECSP21053104A/es unknown
-
2023
- 2023-06-14 US US18/334,632 patent/US20230310483A1/en active Pending
- 2023-10-20 AU AU2023251525A patent/AU2023251525A1/en active Pending
- 2023-11-14 DO DO2023000251A patent/DOP2023000251A/es unknown
- 2023-11-27 JP JP2023199595A patent/JP2024037737A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019403447B2 (en) | 2023-07-27 |
EP3899024A1 (en) | 2021-10-27 |
CO2021009009A2 (es) | 2021-07-30 |
TW202039846A (zh) | 2020-11-01 |
MX2021007503A (es) | 2021-08-05 |
CL2021001643A1 (es) | 2022-01-21 |
AU2023251525A1 (en) | 2023-11-16 |
US20230310483A1 (en) | 2023-10-05 |
JOP20210158A1 (ar) | 2023-01-30 |
JP7394137B2 (ja) | 2023-12-07 |
BR112021011899A2 (pt) | 2021-10-26 |
CA3122432A1 (en) | 2020-06-25 |
KR20210107027A (ko) | 2021-08-31 |
ECSP21053104A (es) | 2021-08-31 |
CR20210395A (es) | 2021-11-05 |
US20220273691A1 (en) | 2022-09-01 |
SG11202106378VA (en) | 2021-07-29 |
AU2019403447A1 (en) | 2021-07-29 |
WO2020132564A1 (en) | 2020-06-25 |
NI202100056A (es) | 2021-12-01 |
IL283967A (en) | 2021-07-29 |
EP3899024A4 (en) | 2023-05-31 |
JP2022514657A (ja) | 2022-02-14 |
DOP2021000130A (es) | 2021-09-30 |
JP2024037737A (ja) | 2024-03-19 |
PE20211755A1 (es) | 2021-09-07 |
CN113544272A (zh) | 2021-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2023000251A (es) | Compuestos oligoméricos que inhiben la expresión de hsd17b13 | |
CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
DOP2019000201A (es) | Compuestos inhibidores del vih | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
SV2018005742A (es) | Inhibidores de mcl-1 macrocíclicos para tratar el cáncer | |
CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
EP4331677A3 (en) | Methods of treating feline coronavirus infections | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
NI201800071A (es) | Compuestos de isoindol | |
EA201890532A1 (ru) | Новые аннелированные бензамиды | |
MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
CL2020002199A1 (es) | Compuesto de anillo de metillactama y uso farmacéutico del mismo. | |
CU20160182A7 (es) | Compuestos derivados de 1,6 naftiridina-diona activos como supresores de mutación sin sentido | |
AR103219A1 (es) | Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento | |
DOP2021000028A (es) | Formulaciones de dendrímeros | |
CO2020001514A2 (es) | Composición farmacéutica para la prevención o el tratamiento de enfermedades cardiovasculares acompañadas por diabetes, que incluye amlodipino, losartán y rosuvastatina, y preparación compuesta que incluye los mismos | |
AR119317A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
AR101474A1 (es) | Composición semioquímica inhibidora de la fijación de copepoditos de piojos de mar | |
AR108792A1 (es) | Composiciones que comprenden timolol | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. |